Once-a-Month Oral Contraceptive
Levonorgestrel Gastric Resident Dosage Form, Levonorgestrel Gastric Retentive Dosage Form
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Oral
-
Intended Duration:
- Short-Acting
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): Lyndra Therapeutics, Massachusetts Institute of Technology
Details
- API: Levonorgestrel
- Target: Progesterone Receptor
-
Mechanism of Action:
- Ovulation Inhibition
- Cervical Mucus Changes
- Endometrial Changes
- Inactive Materials: Poly(sebacic anhydride)- and/or Polydimethylsiloxane (PDMS)-Based Polymer Matrices, Sorona 3015G NC010, Elastollan 1185A10, 1 mm Radiopaque Steel Balls, and Gelatin Capsule
- Regimen: 1 Pill/Month
- MPT: Not Potential MPT
- Promising Attributes: A monthly pill may improve adherence and patient uptake.
Product Status
No public developments since 2019, but method is featured on Lyndra website & highlighted in Gates Foundation publications.
History
2019: Langer & Traverso Labs at MIT announce results of in vivo animal study of LNG-releasing gastric system that remains in the stomach for a month. Lyndra, an MIT-linked startup, announces 13M in grant funding to further develop method.